Patents by Inventor Thomas Lanza

Thomas Lanza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted amides
    Publication number: 20050234061
    Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
    Type: Application
    Filed: April 19, 2005
    Publication date: October 20, 2005
    Inventors: William Hagmann, Linus Lin, Shrenik Shah, Ravindra Guthikonda, Hongbo Qi, Linda Chang, Ping Liu, Helen Armstrong, James Jewell, Thomas Lanza
  • Substituted azetidiones as anti-inflammatory and antidegenerative agents
    Patent number: 5747485
    Abstract: Substituted azetidinones are herein disclosed for use in the treatment of various elastase-mediated diseases.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: May 5, 1998
    Assignee: Merck & Co., Inc.
    Inventors: James Doherty, Conrad Dorn, Philippe Durette, Paul Finke, Malcolm Maccoss, Sander Mills, Shrenik Shah, Soumya Sahoo, William Hagmann, Jeffrey Hale, Thomas Lanza